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A 67-year-old woman with compensated cirrhosis type B associated with hepatocellular carcinoma was started on sorafenib for
multiple pulmonary metastases. The patient developed right upper quadrant pain and high fever 4 weeks later. Imaging revealed
markedenlargementofthegallbladderwithoutcalculi.Followingpercutaneoustranshepaticgallbladderaspiration,hersymptoms
resolved, but the gallbladder remained enlarged. Laparoscopic cholecystectomy was performed. Arteriolar occlusion with intimal
thickeninginthemuscularlayerofthegallbladderwasseensporadically.Thefactthatthispatienthadnoriskfactorsforacalculous
cholecystitis suggested that the cholecystitis resulted from ischemia, implying a strong causal relationship with sorafenib.
1.Introduction
Sorafenib is a multikinase inhibitor that targets the cellular
signal transduction pathways necessary for tumor cell pro-
liferation and angiogenesis [1, 2]. Clinically, sorafenib is the
ﬁrst molecular targeted agent to inhibit tumor progression
and prolong survival in hepatocellular carcinoma (HCC)
[3,4].SorafenibwasapprovedinJapaninMay2009forunre-
sectable advanced HCC, and its use is expanding. We report
herein a patient on sorafenib for pulmonary metastases of
HCC with complicating acute acalculous cholecystitis who
required cholecystectomy. To the best of our knowledge, this
represents the ﬁrst reported case of acalculous cholecystitis
developing during sorafenib therapy, and is signiﬁcant as a
causal relationship with sorafenib was strongly suggested.
2.CaseReport
The patient was a 67-year-old woman with cirrhosis type B
who was referred to our department by her local physician
for two HCC lesions (86mm in S8 and 23mm in S6). Our
Department of Surgery determined that the HCCs were
unresectabledue to poor hepatic functional reserve. Lipiodol
transcatheter arterial chemoembolization (Lip-TACE) was
performed with subsequent radiofrequency ablation (RFA).
In addition, entecavir was started for the cirrhosis type B.
There was recurrence of the multiple intrahepatic metastases
11 months later, for which Lip-TACE with RFA was per-
formed. Thirty-one months later, there were innumerable
pulmonary metastases bilaterally, and sorafenib, 800mg
daily, was started. When sorafenib therapy commenced, her
Eastern Cooperative Oncology Group performance status
(PS) was 0, her platelet count were 7.9 × 104/mm3, and her
Child-Pugh score was 5 points (Class A). She had no history
ofconcurrentdiabetesmellitus,hypertension,ischemicheart
disease, or thromboembolism, nor did she have marked
cytopenia or renal dysfunction that would have been of
concern. She did not experience any adverse reactions
after starting sorafenib, except for Grade 2 hypertension
and Grade 1 hand-foot skin reaction, graded according
to the Common Terminology Criteria for Adverse Events,
Version 3.0. Four weeks after starting sorafenib, the patient
developed right upper quadrant pain (RUQ) and high
fever, for which she received emergency treatment in our2 ISRN Gastroenterology
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Figure 1:(a)GallbladderswellingcannotbeseenonbaselineabdominalCTbeforesorafenibadministration.(b)Ahighlytenseandenlarged
gallbladder can be seen on abdominal CT. There is no thickening of the gallbladder wall. The intrahepatic and common bile ducts are not
dilated, and there are no calculi in the gallbladder or tumorous lesions in the neck of the gallbladder.
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Figure 2:Clearthickeningofthegallbladderwallcannotbeseenon
abdominal ultrasonography, but echoes from biliary debris can be
seen inside a highly tense and enlarged gallbladder. Clear elevated
lesions and calculi cannot be seen in the gallbladder.
department. Blood examination revealed an inﬂammatory
reaction, with a white blood cell count of 6470/mm3,a
neutrophil left shift of 83%, and a C-reactive protein level
of 5.73mg/dL. Although a tendency toward disseminated
intravascular coagulation (DIC), with a marked decrease
in platelet count (3.4 × 104/mm3), prothrombin time INR
of 1.29, and an increase in ﬁbrin degradation products
(15.8μg/dL) was suspected, a ﬁbrinogen 629mg/dL and DIC
score was four. The following laboratory values showed no
marked changes from pre-sorafenib levels: total bilirubin:
1.7mg/dL; direct bilirubin: 0.2mg/dL, albumin: 3.9g/dL;
aspartate aminotransferase: 53IU/L; alanine aminotrans-
ferase: 30IU/L; alkaline phosphatase: 164IU/L; γ-glutamyl
transpeptidase: 20IU/L. Abdominal plain computed tomog-
raphy revealed a markedly enlarged gallbladder (Figure 1),
and abdominal ultrasound (Figure 2) revealed biliary debris
without calculi. She was diagnosed with acute acalculous
cholecystitis, and was admitted on an emergency basis.
Sorafenibwasdiscontinued,andsulbactamsodium,1gdaily,
was started. However, her symptoms did not improve and
DIC score increased on day 2 after admission, percutaneous
transhepatic gallbladder aspiration was performed. Pseu-
domonas aeruginosa and Serratia marcescens were identiﬁed
in the bile. The cholecystitis resolved immediately postop-
eratively, but the gallbladder remained enlarged (Figure 3),
and the RUQ discomfort persisted. Therefore, laparoscopic
cholecystectomy was performed 45 days after admission.
The gallbladder showed no calculi or neoplastic changes,
but macroscopic adenomyomatosis was seen in the fun-
dus. Histological examination revealed chronic cholecystitis
with Rokitansky-Aschoﬀ sinuses and ﬁbromuscular tissue
proliferation. There was also sporadic arteriolar occlusion
associated with intimal thickening in the muscular layer of
the gallbladder (Figure 4).
3. Discussion
Sorafenib is a molecular targeted agent that is already in
widespread use worldwide for malignancies such as renal
carcinoma,coloncancer,breastcancer,andHCC.Therehave
been no reports to date of acalculous cholecystitis occurring
during sorafenib therapy. However, six renal carcinoma cases
and two HCC cases with complicating acute acalculous
c h o l e c y s t i t i so nS o r a f e n i bh a db e e nr e p o r t e dt oB a y e ri n
Japan on the market between April 2008 and June 2010 (not
published). Seven of eight cases were serious. There may
be an increased incidence of acute acalculous cholecystitis.ISRN Gastroenterology 3
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Figure 3: (a) Gallbladder swelling with wall thickness remained on abdominal CT 30 days after admission. (b) Gallblader and cystic duct
were not visualized on three-dimensional spiral CT cholangiography.
(a) (b)
Figure 4: (a) Changes due to chronic cholecystitis can be seen: proliferation of ﬁbromuscular tissue and formation of Rokitansky-Aschoﬀ
sinuses can be seen on the gallbladder wall. (b) Occluded arterioles with thickened vascular endothelium can be seen in the muscular layer
of the gallbladder.
Therehavealreadybeentworeportsofacalculouscholecysti-
tisinpatientstreatedwithsunitinib,whichisanangiogenesis
inhibitor like sorafenib [5, 6], suggesting the potential for
such events to occur with sorafenib.
Critically ill patients frequently develop acute acal-
culous cholecystitis following trauma or major surgery.
Such patients then often go on to develop gangrene and
perforation and have a higher mortality rate than patients
with calculous cholecystitis [7, 8] .C o m m o nr i s kf a c t o r s
for acute acalculous cholecystitis include surgery, severe
trauma, burns, and parenteral nutrition [9], but malignant
metastases to the hepatic hilum [10], hepatic artery infusion
of anticancer drugs [11], diabetes mellitus [12], and other
conditionsarealsoreportedlyinvolved.However,inaddition
to having a good PS (0) when given sorafenib, the present
patient did not have such risk factors or a history of
concurrent diabetes mellitus, hypertension, ischemic heart
disease, or thromboembolism. She also fully satisﬁed the
eligibility criteria for sorafenib treatment, with good hepatic
function(Child-PughClassA)andnomarkedcytopenia.We
therefore strongly suspected that sorafenib was involved in
this patient’s acute acalculous cholecystitis.
Sorafenib presents a high risk for vascular adverse events
such as hypertension, hemorrhage, and arterial throm-
boembolic events (ATEs), such as myocardial ischemia and
myocardial infarction, mediated by the drug’s inhibition
of vascular endothelial growth factor (VEGF) [13]. The
mechanism by which ATEs occurs is not yet understood,
but it has been postulated that homeostasis between the
vascular endothelium and platelets is disturbed by sorafenib-
mediated damage to vascular endothelial cells, allowing
platelets to aggregate more readily on the surface of the
vascular endothelium [14].
Thrombi could not be conﬁrmed in arterioles of the
resected gallbladder because 45 days had passed since the
onset of acute cholecystitis in this patient, but arteriolar
occlusion associated with vascular endothelial thickening
was seen sporadically. This type of vascular remodeling
associated with arteriolar intimal thickening is induced
by hypoxia [15], suggesting that the cause of the acute4 ISRN Gastroenterology
cholecystitis in this patient was gallbladder ischemia rather
than calculus impaction. Based on the above, we postulated
that acute acalculous cholecystitis occurred by the following
mechanism in this patient. The vascular endothelium was
damaged by administering sorafenib, and thrombi formed
in the arterioles of the gallbladder. This resulted in a
further reduction in gallbladder blood ﬂow that was already
reduced by chronic cholecystitis and caused acute acalculous
cholecystitis.
Hepatocellular carcinoma often occurs in cirrhosis.
Chronic cholecystitis and cholecystolithiasis are frequent
complications of cirrhosis, and if acute cholecystitis occurs,
it can easily become serious. We are concerned that there
may be an increased incidence of acute cholecystitis with the
expanding use of sorafenib and recommend caution when
using this drug.
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